Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs [1]

Hepatology

Volumn 42, Issue 6, 2005, Pages 1459-

  Janssen, Harry L A ^a   Lau, George K K ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B;

CHRONIC HEPATITIS; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; LETTER; LONG TERM CARE; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS REPLICATION;

ANTIVIRAL AGENTS; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; NUCLEOSIDES; NUCLEOTIDES; POLYETHYLENE GLYCOLS;

EID: 32944458551     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20951     Document Type: Letter

References (10)

1. Berg T. New perspectives in the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B. HEPATOLOGY 2005;41:1402-1405.
2. Janssen HL, van Zonneveld M, Senturk H, Zeuzem, S, Akarca US, Cakaloglu Y, et al. Pegylated Interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet 2005;365:123-129.
3. Marcellin P, Lau GKK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-1217.
4. Marcellin P, Chang TT, Lin S, Sievert W, Tong M, Arterburn S, et al. Long term efficacy and safety of adefovir dipivoxil (ADV) 10 mg in HBeAg+ chronic hepatitis B (CHB) patients: increasing serologic, virologic and biochemical response over time. HEPATOLOGY 2004;40:655A.
5. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. HEPATOLOGY 2001;33:1527-1532.
6. Lok A. Gastroenterology 2004;126:1932-3 (Response to comments on Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-1722.
7. Lau GKK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-2695.
8. van Nunen AB, Hansen BE, Suh DJ, Lohr HF, Chemello L, Fontaine H, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003;52:420-424.
9. Chan HLY, Hui AY, Wong VWS, Chim AM, Wong ML, Sung JJ, et al. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. HEPATOLOGY 2005;41:1357-1364.
10. van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Murad SD, de Man RA, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. HEPATOLOGY 2004;39:804-810.